This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Switching antidepressant (vortioxetine to tricyclic antidepressants (TCAs)) in adults

Authoring team

Vortioxetine to tricyclic antidepressants (TCAs)

  • is limited experience with this switch so extra caution is required to avoid serotonin syndrome

Switching to dosulepin requires specialist advice and should not be done in primary care due to the increased cardiac risk and toxicity in overdose (1)

To all except clomipramine

Cross-taper

  • cross-tapering, starting with a low dose TCA can usually be undertaken cautiously over 2 to 4 weeks, the speed is determined by individual tolerability

Stop, washout and switch

  • alternatively, stop vortioxetine; wait for a period before starting low dose TCA. Clinicians should decide the duration of the washout period on a case-by-case basis.

To clomipramine

  • cross-tapering is not recommended and should only be undertaken if specialist advice is in place, this is because clomipramine is a potent serotonin reuptake inhibitor so there is a high risk of serotonin syndrome.

Taper, stop and switch

  • gradually reduce the dose of vortioxetine and stop. Start low dose clomipramine the following day

Stop, washout and switch

  • alternatively, stop vortioxetine; wait for a period before starting low dose clomipramine. Clinicians should decide the duration of the washout period on a case-by-case basis

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.